AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9475320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment for galactosaemia
Number of subjects: 0
Study 9475320 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0
Study 9475320 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro analysis of galactose or its close metabolites
Number of subjects: 0
Study 7971582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal Survanta (modified surfactant extracted from cow lung)
Number of subjects: 34
Study 7971582 — intervention group
Group type: COMPARATOR
Intervention: No surfactant treatment (control group)
Number of subjects: 34
Study 2896076 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (200 mg bid)
Number of subjects: 22
Study 2896076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30298024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (priovi) in addition to care as usual (CAU)
Number of subjects: 108
Study 30298024 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) alone
Number of subjects: 108
Study 30298024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (priovi)
Number of subjects: 108
Study 28869842 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualizing and Verbalizing for language comprehension and thinking (V/V); 4 hours per day, 10 weeks, 200 hours of face-to-face instruction
Number of subjects: 28
Study 26354547 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-FII diet
Number of subjects: 20
Study 26354547 — intervention group
Group type: COMPARATOR
Intervention: High-FII diet
Number of subjects: 20
Study 26354547 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 20
Study 23512892 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration via subcutaneous injection twice daily for 16 weeks
Number of subjects: 27
Study 23512892 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration via subcutaneous injection twice daily for 16 weeks
Number of subjects: 27
Study 23512892 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration
Number of subjects: 27
Study 23512892 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 27
Study 21811161 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose regimen (rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, all twice daily for 10 days)
Number of subjects: 115
Study 21811161 — intervention group
Group type: COMPARATOR
Intervention: Half-dose regimen (rabeprazole 10 mg, amoxicillin 500 mg, clarithromycin 250 mg, all twice daily for 10 days)
Number of subjects: 115
Study 21811161 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose regimen
Number of subjects: 115
Study 21811161 — intervention group
Group type: COMPARATOR
Intervention: Half-dose regimen
Number of subjects: 115
Study 19364653 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 161
Study 19364653 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 161
Study 16280375 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme (2 h lesson in each class; 2 h general session with patients and experts; first and second anonymous questionnaires)
Number of subjects: 1776
Study 16280375 — intervention group
Group type: COMPARATOR
Intervention: Control (questionnaires)
Number of subjects: 1776
Study 15330320 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxicillin/sulbactam (AMX-SUL)
Number of subjects: 6
Study 15330320 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin (AZM)
Number of subjects: 6
Study 15330320 — intervention group
Group type: COMPARATOR
Intervention: doxycycline (DOX)
Number of subjects: 6
Study 15330320 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin (LVX)
Number of subjects: 6
Study 11220426 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg dextromethorphan (DM)
Number of subjects: 30
Study 11220426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9243350 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 11
Study 9243350 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin G (CSG)
Number of subjects: 11
Study 8492715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 8
Study 8492715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2856542 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose beclomethasone (200 micrograms bid)
Number of subjects: 9
Study 2856542 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose beclomethasone (1000 micrograms bid)
Number of subjects: 9
Study 2856542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28230581 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized software for handoff communication
Number of subjects: 14
Study 28230581 — intervention group
Group type: COMPARATOR
Intervention: Usual handoff process
Number of subjects: 14
Study 30921005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplements (15 mg capsules/day)
Number of subjects: 133
Study 30921005 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea supplements (600 mg/day epigallocatechin gallate)
Number of subjects: 133
Study 30921005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 28851296 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin antibiotic prescribing guideline
Number of subjects: 0
Study 28851296 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 0
Study 25565680 — intervention group
Group type: EXPERIMENTAL
Intervention: BPMED intervention (text message reminders)
Number of subjects: 120
Study 25565680 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 120
Study 24199224 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 409
Study 24199224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 21371718 — intervention group
Group type: EXPERIMENTAL
Intervention: Open adjunctive ziprasidone (mean final dose 190 ± 92 mg/day) for mean of 79.2 ± 23.2 days
Number of subjects: 25
Study 18288085 — intervention group
Group type: COMPARATOR
Intervention: 3 mg varenicline
Number of subjects: 45
Study 18288085 — intervention group
Group type: COMPARATOR
Intervention: 1 mg varenicline
Number of subjects: 45
Study 18288085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18288085 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 and 30 mg amphetamine
Number of subjects: 45
Study 17022368 — intervention group
Group type: EXPERIMENTAL
Intervention: Streblus asper leaf extract (SAE) solution (80 mg/ml)
Number of subjects: 42
Study 17022368 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 42
Study 12878455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Number of subjects: 90
Study 12878455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12878455 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women at 12-14 weeks
Number of subjects: 90
Study 12878455 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women at 30-34 weeks
Number of subjects: 90
Study 12878455 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk pregnancies
Number of subjects: 90
Study 11520467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 201
Study 11520467 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 201
Study 8987188 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado enriched diet (2000 Kcal, lipids 53% MFA 49 g saturated/unsaturated ratio 0.54)
Number of subjects: 67
Study 8987188 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet (MFA 34 g, saturated/unsaturated ratio 0.7)
Number of subjects: 67
Study 2000786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 82
Study 2000786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 6124083 — intervention group
Group type: EXPERIMENTAL
Intervention: Loud noise exposure (95 dBA or 100 dBA)
Number of subjects: 0
Study 31006815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS) 50,000 IU
Number of subjects: 306
Study 31006815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 31006815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 306
Study 31006815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Status (measured by plasma retinol)
Number of subjects: 306
Study 28617530 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12
Number of subjects: 90
Study 28617530 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment group (no folic acid and vitamin B12)
Number of subjects: 90
Study 26036418 — intervention group
Group type: EXPERIMENTAL
Intervention: Devitalized moss transplants
Number of subjects: 2
Study 26036418 — intervention group
Group type: COMPARATOR
Intervention: Irrigated moss transplants
Number of subjects: 2
Study 23306427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 100 mg of rebamipide three times a day
Number of subjects: 75
Study 23306427 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 100 mg celecoxib twice daily
Number of subjects: 75
Study 21292169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg twice daily
Number of subjects: 518
Study 21292169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan 0.5 mg once daily
Number of subjects: 518
Study 21292169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 21292169 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan (both dosages)
Number of subjects: 518
Study 19719843 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol with rFSH and pre‐treatment with hCG (200 IU/day for 7 days)
Number of subjects: 2
Study 19719843 — intervention group
Group type: COMPARATOR
Intervention: Long protocol with rFSH (control group)
Number of subjects: 2
Study 19719843 — intervention group
Group type: EXPERIMENTAL
Intervention: Long protocol with rFSH and pre‐treatment with hCG
Number of subjects: 2
Study 17432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation or reconstruction of uncinate process during nasal sinus opening surgery
Number of subjects: 30
Study 17432347 — intervention group
Group type: COMPARATOR
Intervention: Traditional functional endoscopic sinus surgery (FESS)
Number of subjects: 30
Study 15226339 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase every 2 weeks for 12 months
Number of subjects: 577
Study 15226339 — intervention group
Group type: COMPARATOR
Intervention: Heparin every 2 weeks for 12 months
Number of subjects: 577
Study 11520428 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplement
Number of subjects: 16
Study 11520428 — intervention group
Group type: COMPARATOR
Intervention: Vegan diet
Number of subjects: 16
Study 9517598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 microg
Number of subjects: 306
Study 9517598 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 500 microg
Number of subjects: 306
Study 7831624 — intervention group
Group type: EXPERIMENTAL
Intervention: salmon calcitonin nasal spray (200 IU every other day, n = 22)
Number of subjects: 44
Study 7831624 — intervention group
Group type: COMPARATOR
Intervention: calcium alone (n = 22)
Number of subjects: 44
Study 7831624 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 44
Study 3050006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy for 7 days
Number of subjects: 27
Study 3050006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31506734 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum Glide Path motion (OGP)
Number of subjects: 30
Study 31506734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rotation (CR) with HyFlex EDM Glide Path Files
Number of subjects: 30
Study 31506734 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation with stainless steel K‐files (SS)
Number of subjects: 30
Study 30252054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 14
Study 30252054 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 14
Study 30252054 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 14
Study 27090586 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplanar reformatted method for estimating right-to-left ventricular ratios
Number of subjects: 10
Study 27090586 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial method for estimating right-to-left ventricular ratios
Number of subjects: 10
Study 27090586 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Miller score for estimating thrombus burden
Number of subjects: 10
Study 27090586 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Miller method for estimating thrombus burden
Number of subjects: 10
Study 27090586 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Miller method for estimating thrombus burden
Number of subjects: 10
Study 26071025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity functional electrical stimulation (FES)
Number of subjects: 15
Study 26071025 — intervention group
Group type: COMPARATOR
Intervention: Natural sitting condition
Number of subjects: 15
Study 23737323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 142
Study 23737323 — intervention group
Group type: COMPARATOR
Intervention: Topical nifedipine ointment (5 min twice daily for 4 weeks)
Number of subjects: 142
Study 23737323 — intervention group
Group type: COMPARATOR
Intervention: Topical nifedipine ointment
Number of subjects: 142
Study 23737323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy (LIS) and Topical nifedipine ointment
Number of subjects: 142
Study 22078193 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Number of subjects: 130
Study 22078193 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days followed by misoprostol 400 mcg vaginally every 3 h up to a maximum of five doses
Number of subjects: 130
Study 19930851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative warming using a forced-air warmer with an upper body blanket (warming group)
Number of subjects: 24
Study 19930851 — intervention group
Group type: COMPARATOR
Intervention: No intra-operative warming (non-warming group)
Number of subjects: 24
Study 19930851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operative warming using a forced-air warmer
Number of subjects: 24
Study 19930851 — intervention group
Group type: COMPARATOR
Intervention: No intra-operative warming
Number of subjects: 24
Study 16779529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 77
Study 16779529 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 77
Study 15040091 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic bambuterol capsule
Number of subjects: 20
Study 15040091 — intervention group
Group type: COMPARATOR
Intervention: Imported bambuterol tablet
Number of subjects: 20
Study 10890304 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive alcohol counseling
Number of subjects: 165
Study 10890304 — intervention group
Group type: COMPARATOR
Intervention: Brief assessment followed by feedback of risky alcohol consumption
Number of subjects: 165
Study 8636453 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of metronidazole 25% dental gel
Number of subjects: 30
Study 8636453 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling
Number of subjects: 30
Study 1545086 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean Room (CR) therapy
Number of subjects: 30
Study 1545086 — intervention group
Group type: COMPARATOR
Intervention: Common sickroom (non-clean room)
Number of subjects: 30
Study 6495025 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide myelography
Number of subjects: 122
Study 6495025 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography
Number of subjects: 122
Study 31282575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sniffing position using channelled (KingVision®) videolaryngoscope
Number of subjects: 0
Study 31282575 — intervention group
Group type: COMPARATOR
Intervention: Neutral position using non‐channelled (C‐MAC®) videolaryngoscope
Number of subjects: 0
Study 28716519 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus Ezetimibe
Number of subjects: 0
Study 28716519 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study 26944728 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal approach
Number of subjects: 100
Study 26944728 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 100
Study 24713413 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 507
Study 24713413 — intervention group
Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 507
Study 22723578 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (INS group)
Number of subjects: 58
Study 22723578 — intervention group
Group type: COMPARATOR
Intervention: Triple oral therapy (TOT group)
Number of subjects: 58
Study 21171670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan (150 mg twice daily)
Number of subjects: 30
Study 21171670 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily)
Number of subjects: 30
Study 21171670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lesogaberan and esomeprazole
Number of subjects: 30
Study 18487004 — intervention group
Group type: EXPERIMENTAL
Intervention: Analyze Later
Number of subjects: 13239
Study 18487004 — intervention group
Group type: COMPARATOR
Intervention: Analyze Early
Number of subjects: 13239
Study 15781539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33% bupivacaine
Number of subjects: 42
Study 15781539 — intervention group
Group type: COMPARATOR
Intervention: 0.33% ropivacaine
Number of subjects: 42
Study 14599331 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based videoconferencing (n=24)
Number of subjects: 39
Study 14599331 — intervention group
Group type: COMPARATOR
Intervention: Standard classroom procedure (n=15)
Number of subjects: 39
Study 9703606 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller access laparoscopic inguinal hernia repair (LH)
Number of subjects: 40
Study 9703606 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic inguinal hernia repair (LH)
Number of subjects: 40
Study 7493230 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82
Study 7493230 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study 1695070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 12
Study 1695070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (300 mg twice daily)
Number of subjects: 12
Study 1695070 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg or 300 mg)
Number of subjects: 12
Study 1695070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 686240 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of tinidazole twice daily for 7 days
Number of subjects: 45
Study 686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 2,000 mg of tinidazole
Number of subjects: 45
Study 686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosages of tinidazole
Number of subjects: 45
Study 30950715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation in WATER trial (30cc to 80cc prostates)
Number of subjects: 217
Study 30950715 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation in WATER II trial (80cc to 150cc prostates)
Number of subjects: 217
Study 28203695 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (2 × 30 minutes/week)
Number of subjects: 116
Study 28203695 — intervention group
Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study 25469723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MOX) 400 mg once daily for 7 days
Number of subjects: 40
Study 25469723 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 7 days
Number of subjects: 40
Study 25469723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MOX)
Number of subjects: 40
Study 25469723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23683444 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 0.5mg.kg(‐1)
Number of subjects: 80
Study 23683444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5mg.kg(‐1)
Number of subjects: 80
Study 23683444 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2μg.kg(‐1)
Number of subjects: 80
Study 23683444 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline 5mL)
Number of subjects: 80
Study 22000683 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support programme in primary care practices
Number of subjects: 51
Study 22000683 — intervention group
Group type: COMPARATOR
Intervention: Control practices (no training and support programme)
Number of subjects: 51
Study 18471084 — intervention group
Group type: EXPERIMENTAL
Intervention: PfMSP5 or PvMSP5 immunoglobulin (Ig)G
Number of subjects: 340
Study 18471084 — intervention group
Group type: EXPERIMENTAL
Intervention: PfMSP5 or PvMSP5 immunoglobulin (Ig)M
Number of subjects: 340
Study 18471084 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG responses for PfMSP5
Number of subjects: 340
Study 18471084 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG responses for PvMSP5
Number of subjects: 340